Immatics N.V. revenue breakdown overview

Immatics N.V. revenue for the last year amounted to 59.60 M USD, the most of which — 58.38 M USD — came from its highest performing source at the moment, T Cell Redirecting Immunotherapies, the year earlier bringing 181.64 M USD. The greatest contribution to the revenue figure was made by Germany — last year it brought Immatics N.V. 58.38 M USD, and the year before that — 181.64 M USD.